Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have reported new glucagon-like peptide 1 receptor (GLP-1R) agonists described as potentially useful for the treatment of diabetes, obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).
Recent patents from Opna Bio AG detail new transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of arrhythmogenic right ventricular cardiomyopathy, cancer, Holt-Oram syndrome, neurofibromatosis type 2, polycystic kidney and Alzheimer’s disease.
A Contineum Therapeutics Inc. patent describes a crystalline form of lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of brain cancer, glioblastoma, idiopathic pulmonary fibrosis, inflammatory disorders, multiple sclerosis, neurodegeneration, neuropathic pain and scleroderma, among others.
Work at the Korea Institute of Radiological and Medical Sciences and Korea Research Institute of Chemical Technology has led to the identification of new poly(ADP-ribose) polymerase tankyrase (TNKS) inhibitors potentially useful for the treatment of cancer.
Shwachman-Diamond syndrome is an inherited bone marrow failure syndrome characterized by exocrine pancreatic insufficiency, cytopenia, growth restriction and skeletal abnormalities, and for which primary treatment is allogeneic hematopoietic stem cell transplantation, which is associated with significant toxicity.
The brain is a vulnerable organ that is compromised in the absence of energy production. Reduced fuel delivery to the brain correlates with aging and is an early predictor of potential neurological dysfunction, such as what occurs in Parkinson’s disease.
The mechanisms contributing to prostate cancer progression are still incompletely understood. There has been increasing attention on myosin heavy chain 6 (MYH6) for its involvement in cellular processes beyond the heart.
Antimicrobial peptides, existing in animals and plants, are the first line of defense of the organisms against bacteria. Thymol and carvacrol are two monoterpenoids with known antibacterial activity exerted through bacterial cell membrane structural disruption, which contributes to a lower risk of developing resistance compared to antibiotics acting against specific targets on cells.
Hematopoietic progenitor kinase 1 (HPK1) plays a relevant role in regulating T-cell, B-cell and dendritic cell function. As its inactivation both in vitro and in vivo contributes to tumor growth inhibition, HPK1 is considered a therapeutic target to explore in cancer immunotherapy.